Markets
· 1 article
Notable
Moderna lifts 2026 sales growth view to 15%-25%
Moderna (MRNA) raised its outlook on Friday November 6 and now expects 2026 revenue to grow 15% to 25%, well above its earlier forecast. Third-quarter sales and earnings beat Wall Street estimates. The company swung to a profit from a loss a year earlier. CEO Stéphane Bancel credited newer products and a wider geographic reach.
Sources
Moderna raises 2026 sales growth view to 15%-25%
The whole story · updated
CN
CNBC
·
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction